文献速递肺栓塞与肺血管病呼吸危重症与机械通气

儿科心脏ICU肺动脉高压患者的死亡率分析

Mortality from Pulmonary Hypertension in the Pediatric Cardiac ICU.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

该研究基于儿科心脏重症监护联盟5年数据,分析2602例肺动脉高压医疗入院,死亡率为10%,其他医疗入院为3.9%。多变量分析显示有创通气、无创通气、心肺复苏和血管活性药物输注与死亡率独立相关,其中血管活性药物是早期死亡的主要风险因素。入院第1或第2天同时接受有创通气和血管活性药物者死亡率超过未接受者的五倍。

要点

  • 肺动脉高压患儿在儿科心脏ICU死亡率高(10%),显著高于其他医疗入院(3.9%)。
  • 有创通气、无创通气、心肺复苏和血管活性药物输注与死亡率独立相关。
  • 入院早期同时接受有创通气和血管活性药物者死亡率超过29%,未接受者<5%。

核心结论

  • 肺动脉高压患者入住儿科心脏重症监护病房的死亡率高,入院早期接受有创通气和血管活性药物者死亡率显著升高。

研究设计与样本

  • 回顾性多中心队列研究,纳入儿科心脏重症监护联盟机构5年内因肺动脉高压入院的医疗病例共2602例。

主要发现

  • 肺动脉高压入院死亡率为10%,其他医疗入院为3.9%。
  • 与死亡率独立相关的因素包括有创通气(调整OR 44.8,95%CI 6.2-323)、无创通气(OR 19.7,95%CI 2.8-140)、心肺复苏(OR 8.9,95%CI 5.6-14.1)和血管活性药物输注(OR 4.8,95%CI 2.6-8.8)。
  • 入院第1天同时接受有创通气和血管活性药物者死亡率为29.2%,第2天为28.6%,未接受两者者死亡率<5%。
  • 血管活性药物是早期死亡的主要风险因素,入院第2天存在时平均增加绝对死亡风险6.4%。

临床怎么用

  • 对于儿科心脏ICU的肺动脉高压患者,入院早期接受有创通气或血管活性药物提示预后不良,可与家属沟通预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Patients with pulmonary hypertension (PH) admitted to pediatric cardiac ICUs are at high risk of mortality. Objectives: To identify factors associated with mortality in cardiac critical care admissions with PH. Methods: We evaluated medical admissions with PH to Pediatric Cardiac Critical Care Consortium institutions over 5 years. PH was standardly defined in the clinical registry by diagnosis and/or receipt of intensive care-level pulmonary vasodilator therapy. Multivariable logistic regression identified independent associations with mortality. Measurements and Main Results: We analyzed 2,602 admissions; mortality was 10% versus 3.9% for all other medical admissions. Covariates most strongly associated with mortality included invasive ventilation (adjusted odds ratio, 44.8; 95% confidence interval, 6.2-323), noninvasive ventilation (19.7; 2.8-140), cardiopulmonary resuscitation (8.9; 5.6-14.1), and vasoactive infusions (4.8; 2.6-8.8). Patients receiving both invasive ventilation and vasoactive infusions on admission Days 1 and 2 had an observed mortality rate of 29.2% and 28.6%, respectively, compared with <5% for those not receiving either. Vasoactive infusions emerged as the dominant early risk factor for mortality, increasing the absolute risk of mortality on average by 6.4% when present on admission Day 2. Conclusions: Patients with PH admitted to pediatric cardiac critical care units have high mortality rates. Those receiving invasive ventilation and vasoactive infusions on Day 1 or Day 2 had an observed mortality rate that was more than fivefold greater than that of those who did not. These data highlight the illness severity of patients with PH in this setting and could help inform conversations with families regarding the prognosis.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Morell E, Gaies M, Fineman JR, et al. Mortality from Pulmonary Hypertension in the Pediatric Cardiac ICU. Am J Respir Crit Care Med. 2021. PMID: 33798036. doi:10.1164/rccm.202011-4183OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。